• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 9, Issue 4
  3. Author

Online ISSN: 2515-8260

Volume9, Issue4

Efficacy of orally disintegrating tablet of ondansetron 4mg sublingually compared to ondasetron 4mg intravenousin the management of post-operative nausea and vomiting in patients undergoing elective laparoscopic surgeries under general anesthesia: A non-inferiority study

    Dr. Leelavathi Bikumalla, Dr. Swathi Appagalla, Dr. Rajitha Suragouni, Dr. Sarada Devi Vankayalapati, Dr. Surender Pasupuleti

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 4, Pages 544-551

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Background: Orally disintegrating tablet (ODT) of ondansetronis an attractive option for
prevention and management of post-operative nausea and vomiting (PONV) compared to
intravenous ondansetron. It is given sub-lingually and automatically gets dissolved and hence
convenient. There is no need of water and hence it does not interfere with the fasting status of
the patients. As it is absorbed by oral mucosa, its bioavailability is high. This is unique thing
about ODT of ondansetronand hence attracts its use.
Keywords:
    ODT ondansetron can be used to prevent post operative nausea and vomiting instead of IV ondansetron as both are equally good and this will also be useful in those who do want to avoid intravenous injections as much as possible
  • PDF (243 K)
  • XML
(2022). Efficacy of orally disintegrating tablet of ondansetron 4mg sublingually compared to ondasetron 4mg intravenousin the management of post-operative nausea and vomiting in patients undergoing elective laparoscopic surgeries under general anesthesia: A non-inferiority study. European Journal of Molecular & Clinical Medicine, 9(4), 544-551.
Dr. Leelavathi Bikumalla, Dr. Swathi Appagalla, Dr. Rajitha Suragouni, Dr. Sarada Devi Vankayalapati, Dr. Surender Pasupuleti. "Efficacy of orally disintegrating tablet of ondansetron 4mg sublingually compared to ondasetron 4mg intravenousin the management of post-operative nausea and vomiting in patients undergoing elective laparoscopic surgeries under general anesthesia: A non-inferiority study". European Journal of Molecular & Clinical Medicine, 9, 4, 2022, 544-551.
(2022). 'Efficacy of orally disintegrating tablet of ondansetron 4mg sublingually compared to ondasetron 4mg intravenousin the management of post-operative nausea and vomiting in patients undergoing elective laparoscopic surgeries under general anesthesia: A non-inferiority study', European Journal of Molecular & Clinical Medicine, 9(4), pp. 544-551.
Efficacy of orally disintegrating tablet of ondansetron 4mg sublingually compared to ondasetron 4mg intravenousin the management of post-operative nausea and vomiting in patients undergoing elective laparoscopic surgeries under general anesthesia: A non-inferiority study. European Journal of Molecular & Clinical Medicine, 2022; 9(4): 544-551.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 71
  • PDF Download: 104
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus